Company Encyclopedia
View More
name
Kingdomway
002626.SZ
Xiamen Kingdomway Group Company engages in the manufacturing and sale of the nutrition and health products in China and internationally. The company also provides dietary supplements, functional foods, and sports nutritions. It offers its products under the Doctor’s Best, Zipfizz, Kingdaway, Labrada, Prosupps, Wu Kun, Viactiv, LeanBody, and Jinlexin brands. It sells its products through online platforms and supermarkets.
3.120 T
002626.SZMarket value -Rank by Market Cap -/-

Financial Score

15/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking32/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE11.26%B
    • Profit Margin13.77%B
    • Gross Margin42.85%B
  • Growth ScoreB
    • Revenue YoY12.06%B
    • Net Profit YoY89.83%A
    • Total Assets YoY42.90%A
    • Net Assets YoY13.48%B
  • Cash ScoreB
    • Cash Flow Margin726.34%B
    • OCF YoY12.06%B
  • Operating ScoreC
    • Turnover0.49C
  • Debt ScoreC
    • Gearing Ratio45.31%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Kingdomway: Subsidiary obtains invention patent for "Preparation of 6-Chloro-6-Oxocaproic Acid Ethyl Ester"

    Kingdomway and its subsidiary Xiamen Kingdomway Vitamin Co., Ltd. have obtained an invention patent issued by the National Intellectual Property Administration, with the patent name "A Continuous Preparation Device and Method for 6-Chloro-6-Oxocaproic Acid Ethyl Ester," patent number ZL202310830368.X, with a patent term of 20 years. This invention belongs to the field of organic synthesis and features mild conditions, high yield, environmental friendliness, and low cost. Although this patent does not significantly impact the company's operations, it contributes to technological innovation and enhances core competitiveness

    Zhitong·
    SZ
    002626
    +1.30%
    Zhitong·
    SZ
    002626
    +1.30%

    Xi'an Shaangu Power Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025

    Xi'an Shaangu Power Co., Ltd. reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 7,185.53 million compared to CNY 7,289.34 million a year ago. Net income was CNY 617.48 million compared to CNY 666.17 million a year ago.Basic earnings per share from continuing operations was CNY 0.36 compared to CNY 0.39 a year ago. Diluted earnings per share from continuing operations was CNY 0.36 compared to CNY 0.39 a year ago.

    marketscreener·
    SH
    601369
    -1.06%
    marketscreener·
    SH
    601369
    -1.06%

    Kingdomway released its performance for the first three quarters, with a net profit attributable to the parent company of 361 million yuan, a year-on-year increase of 63.47%

    According to the Zhitong Finance APP, Kingdomway released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 2.604 billion yuan, a year-on-year increase of 11.16%. The net profit attributable to shareholders of the listed company was 361 million yuan, a year-on-year increase of 63.47%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 349 million yuan, a year-on-year increase of 56.22%

    Zhitong·
    SZ
    002626
    +1.30%
    Zhitong·
    SZ
    002626
    +1.30%

    Xiamen Kingdomway Group's Worm Infection Drug Approved in China

    (MT Newswires) -- Chinese agricultural officials approved Xiamen Kingdomway Group's (SHE:002626) praziquantel antihelmintic drug, according to a Thursday filing by the fortified food and feed additive manufacturer with the Shenzhen bourse. The registration validity of the worm infection drug is five years, from Sept. 3, 2025, to Sept. 2, 2030.

    marketscreener·
    SZ
    002626
    +1.30%
    marketscreener·
    SZ
    002626
    +1.30%

    Kingdomway's subsidiary has obtained the approval number for veterinary drug products

    According to the Zhitong Finance APP, Kingdomway announced that its holding subsidiary, Jiangsu Chengxin Pharmaceutical Co., Ltd., recently received the veterinary drug product approval number issued by the Ministry of Agriculture and Rural Affairs of the People's Republic of China. Generic name: Praziquantel, veterinary drug product approval number: Veterinary Drug Original Character 102091173

    Zhitong·
    SZ
    002626
    +1.30%
    Zhitong·
    SZ
    002626
    +1.30%
    © 2025 Longbridge｜Disclaimer